RecruitingPhase 1NCT05901285
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
Sponsor
Vaxiion Therapeutics
Enrollment
43 participants
Start Date
Nov 2, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) as a single agent as well as in combination with Investigator's choice of nivolumab or pembrolizumab in patients with advanced solid tumors. VAX014 is a targeted oncolytic agent designed to kill tumor cells following intratumoral injection into advanced solid tumors.
Eligibility
Min Age: 18 Years
Inclusion Criteria24
- Age 18+
- Informed consent
- Histological or cytopathological confirmed diagnosis of a locally advanced or metastatic solid tumor
- Progression following at least one prior standard treatment or intolerant of standard treatments.
- \[Dose Escalation\] Availability of archival or fresh tumor tissue
- \[Expansion\] Willing to undergo biopsy of the tumor to be injected prior to the initial VAX014 injection (may provide archival tissue instead if approved by Medical Monitor)
- No available SOC therapy that would confer clinical benefit
- \[Dose escalation\] At least one cutaneous, subcutaneous, or nodal injectable tumor (between 1 and 10 cm in largest diameter) that can be injected by direct palpation or with the assistance of ultrasound without the need for interventional radiology
- \[Expansion\] At least one injectable tumor (>=0.5cm in largest diameter) that can be injected either with or without the need for interventional radiology
- \[Expansion\] Appropriate for treatment with either nivolumab or pembrolizumab
- \[Expansion\] Progression following at least one prior regimen containing PD-1 directed immune checkpoint blockade
- Measurable disease by RECIST v1.1
- ECOG Performance Status of 0, 1, or 2
- Resolution of any toxicity associated with prior therapy to ≤ Grade 1 (Residual toxicity of Grade 2 may be allowed following discussion with Medical Monitor)
- Adequate hematologic function defined as:
- Absolute neutrophil count >=1,500/uL
- Platelet count >=100,000/uL
- \[Expansion\] Hemoglobin >=9 gm/dL
- Adequate hepatic function defined as:
- Total bilirubin ≤ 1.5 x ULN
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN
- \. Adequate coagulation defined as:
- International normalized ratio (INR) ≤ 1.5 x ULN or prothrombin time (PT) ≤ 1.5 x ULN
- Partial thromboplastin time (PTT) or activated PTT (aPTT) ≤ 1.5 x ULN 18. Serum creatinine ≤ 1.5 x ULN or estimated GFR ≥ 60 mL/min/1.73 m2 (per MDRD GFR formula) 19. Women of childbearing potential must have a negative serum pregnancy test 20. All subjects of childbearing potential must be willing to consent to using effective contraception (as determined by the Investigator) while on treatment and for 3 months after their participation in the study ends
Exclusion Criteria17
- Injectable tumor not sufficiently distanced from critical structures (e.g., major airway, neurovascular structure) where post injection swelling may place the subject at unacceptable risk
- ≤ 21 days from prior anticancer therapy and C1D1 (e.g., chemotherapy, immunotherapy, intralesional therapy, irradiation therapy)
- Known CNS metastases or leptomeningeal carcinomatosis, unless adequately treated and clinically stable off steroids for ≥ 14 days from C1D1
- Severe infection requiring systemic antibiotic therapy or hospitalization for treatment of injection within 2 weeks of the first injection of VAX014
- Need for systemic immunosuppressive therapy (≤10 mg of prednisone equivalent, or one time pulse steroids excepted)
- Active autoimmune disease requiring systemic immunosuppressive therapy
- No active lung disease or pneumonitis
- No history of Grade 4 toxicity in response to prior PD-1 blockade
- Any other malignancy likely to require treatment in the next 2 years (exceptions include cancer such as basal or squamous cell skin cancers, noninvasive cancer of the cervix, and local prostate cancer)
- Known active infection with tuberculosis or HIV
- Active Hepatitis B or C
- \[Females\] pregnant or breastfeeding
- Clinically significant cardiovascular abnormalities including:
- ≤ 12 months from prior MI
- Unstable angina pectoris
- ≤ 6 months from NYHA classification >3 CHF
- \. Medical or psychological condition that places the subject at undue risk with study participation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVAX014
Intratumorally administered oncolytic agent comprised of recombinant bacterial minicells. VAX014 is not infectious and is not capable of replication
COMBINATION_PRODUCTNivolumab or pembrolizumab
VAX014 will be given in combination with Investigator's choice of nivolumab or pembrolizumab.
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05901285
Related Trials
Study in Advanced Solid Tumor Patients
NCT0730094311 locations
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
NCT0683300813 locations
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT0721383011 locations
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT0614703715 locations
HEC169096 in Participants With Advanced Solid Tumors
NCT054516021 location